Low and fixed dose of hydroxyurea is effective and safe in patients with HbSβ+ thalassemia with IVS1‐5(G→C) mutation
- 24 December 2014
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 62 (6) , 1017-1023
Abstract
Background Despite compelling evidence that hydroxyurea is safe and effective in sickle cell disease, it is prescribed sparingly due to several barriers like knowledge gaps in certain genotypes, apprehension about its safety and toxicity, and limited resources. We undertook this study to find out the efficacy and safety of HU in patients with HbSβ+-thalassemia with IVS1–5(G→C) mutation. Procedure We registered 318 patients with HbSβ+-thalassemia with IVS1–5(G→C) mutation. Of these, 203 were enrolled for hydroxyurea treatment at a low and fixed dose of 10 mg/kg/day. One hundred four patients (Group-I: 37 children and Group-II: 67 adults) with ≥2 years of hydroxyurea treatment were studied. Results The rate of vaso-occlusive crises, requirement of blood transfusion and rate of hospitalization reduced from 3 to 0.5, 1 to 0 and 1 to 0 in Group-I and 3 to 0, 1 to 0 and 0.5 to 0 in Group-II respectively after HU therapy (P < 0.0001). %HbF level, hemoglobin, MCV and MCH increased significantly, whereas HbS, WBC, platelet count, serum-bilirubin and LDH levels decreased significantly after HU therapy. It has been observed that along with fairly subtle hematological changes following HU therapy, there was a substantial clinical improvement occurred in these patients. Transient myelotoxicity was observed in 4.8%. There was minimal gonadal toxicity without affecting reproductive function. Conclusion In view of easy affordability, better acceptability, minimal toxicity, the need of infrequent monitoring and its potential effectiveness, low and fixed dose of hydroxyurea is suitable for treatment of patients with HbSβ+-thalassemia in resource poor setting. Pediatr Blood Cancer 2015;62:1017–1023.Keywords
Funding Information
- Department of Science and Technology (DST), New Delhi
- Indian Council for Medical Research (ICMR), New Delhi, India
- National Health Mission (NHM), Odisha, India
This publication has 38 references indexed in Scilit:
- The effect of hydroxcarbamide therapy on survival of children with sickle cell diseaseBritish Journal of Haematology, 2013
- Candidate Sequence Variants and Fetal Hemoglobin in Children with Sickle Cell Disease Treated with HydroxyureaPLOS ONE, 2013
- How I use hydroxyurea to treat young patients with sickle cell anemiaBlood, 2010
- Higher fetal hemoglobin concentration in patients with sickle cell disease in eastern India reduces frequency of painful crisisEuropean Journal of Haematology, 2009
- Adverse Effects of a Clinically Relevant Dose of Hydroxyurea Used for the Treatment of Sickle Cell Disease on Male Fertility EndpointsInternational Journal of Environmental Research and Public Health, 2009
- Advances in the use of hydroxyureaHematology-American Society Hematology Education Program, 2009
- Hydroxyurea in sickle cell disease—A study of clinico-pharmacological efficacy in the Indian haplotypeBlood Cells, Molecules, and Diseases, 2009
- A cell stress signaling model of fetal hemoglobin induction: what doesn't kill red blood cells may make them strongerExperimental Hematology, 2008
- Effect of Hydroxyurea on the Frequency of Painful Crises in Sickle Cell AnemiaNew England Journal of Medicine, 1995
- Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia.Journal of Clinical Investigation, 1984